Almost every common GLP-1 side effect traces to one mechanism: these medications slow how fast food leaves your stomach. Nausea, early fullness, reflux, constipation, and burping all follow from that single fact. The pattern is front-loaded — worst in the weeks after each dose increase, easing as your body adapts — and only a short list of rare events needs a clinician the same day.
That is the whole clinical position. The rest of this page is the map: what happens, how often, why, what resolves on its own, and where the red lines are. Where a symptom needs its own playbook, we link down to it.
It’s mostly one mechanism
Semaglutide and tirzepatide mimic GLP-1, a hormone your gut releases after meals. Three effects are settled: slower gastric emptying, quieter appetite signaling in the hypothalamus and hindbrain, and insulin release that ramps up only when glucose is high. Tirzepatide adds a second incretin, GIP. (The molecule-level story lives at semaglutide.)
The slowed stomach explains most of the list. Food that sits longer presses upward: nausea, reflux, burping. It moves through slower: constipation. It fills you sooner: early satiety, sometimes before the protein is in. And eating far less has consequences of its own: fatigue, occasionally lightheadedness.
The common cluster
STEP 1 (Wilding et al., NEJM 2021 — 1,961 adults, −14.9% mean body weight at week 68) and SURMOUNT-1 (Jastreboff et al., NEJM 2022 — 2,539 adults, up to −20.9% at week 72) are where the benefit numbers come from. The same papers carry the cost side, and both report the same shape: gastrointestinal complaints led the adverse-event tables, most were mild to moderate, and they clustered during dose escalation rather than persisting through the trial.
Ranked roughly by how often they come up:
- Nausea. The most common side effect in the class. It peaks in the 24–48 hours after injection and in the first weeks after a dose increase, then fades. The tactics that blunt it — timing, food order, what to skip — live in GLP-1 nausea hacks.
- Early fullness. Mostly, this is the drug working. It becomes a side effect when you can’t eat enough to hit your protein floor — more on that two sections down.
- Constipation. Slower transit, less food, and usually less water, stacked. Of the whole cluster, it’s the one most likely to outlast titration if unmanaged. The playbook is at GLP-1 constipation.
- Heartburn and reflux. A fuller stomach for longer means more pressure at the valve on top. GLP-1 heartburn and reflux covers what helps — and when reflux is a sign the dose is ahead of your gut.
- Burping, including sulfur burps. The leading explanation is food fermenting during its longer stay. Unpleasant, benign, and it usually improves with the same moves that help nausea and reflux.
- Diarrhea. Common, real, and the least mechanically tidy of the group — incretins change gut motility in ways beyond emptying, and this one is less pinned down. It often alternates with constipation in the same person.
- Fatigue. You are suddenly eating much less than your body is calibrated for. Expected in the first weeks; tell your clinician if it persists after your dose has been stable for a month.
- Injection-site reactions. Redness or a small itchy welt. Mild and local. Rotate between abdomen, thigh, and the back of the upper arm.
- Hair shedding. A few months in, some people shed more than usual. That’s telogen effluvium — follicles reacting to rapid weight loss itself, the same pattern seen after bariatric surgery — and it typically resolves on its own.
One more, which almost nobody files as a complaint: many people simply want alcohol less. The evidence here is thin — small trials and secondary analyses, no large RCT — so call it probable, not proven. Two practical notes either way: alcohol sitting on a slowed stomach hits harder than you expect, and its calories compete directly with your protein target.
The titration ladder is the treatment
Semaglutide steps 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, moving roughly every 4 weeks. Tirzepatide starts at 2.5 mg and steps by 2.5 mg every 4 weeks toward a maintenance dose of 10–15 mg. Both labels say the same thing about the schedule: slow down if side effects demand it.
That instruction is not a disclaimer — it is the side-effect management plan. Each dose increase restarts a short adaptation window; each hold lets your gut catch up. Sitting at 0.5 mg for an extra month is the label working as designed, not a failure of willpower. The GI cluster above resolves for most people because titration paces the mechanism, not because they white-knuckled it.
One asymmetry between the molecules: tirzepatide’s added GIP activity may soften nausea at its higher doses. No head-to-head trial has settled this. Hold it loosely.
The side effect you can’t feel
Part of the weight you lose on a GLP-1 is muscle. DXA substudies within the STEP and SURMOUNT programs measured it: lean mass, not only fat. Whether that matters for strength, function, or fracture risk ten years out has not been studied. We don’t know.
What is known is the countermeasure, and it’s boring: resistance training twice a week and protein around 1.2–1.6 g per kilogram of body weight per day. Early fullness makes the protein target the hard part — which is why it appears on the side-effect list above rather than in a footnote.
Gallstones: partly the drug, mostly the speed
Rapid weight loss raises gallstone risk however you achieve it — aggressive diets and bariatric surgery do it too, because bile chemistry shifts when fat mobilizes fast. The GLP-1 trials recorded more gallbladder events than placebo. Who is actually at risk, what an attack feels like, and when imaging makes sense is covered in GLP-1 and your gallbladder.
For this map, one line matters: pain under the right ribs, especially after a fatty meal, is not routine nausea. Treat it as a same-day call.
The same-day list
Everything above is discomfort. This section is danger. Contact your clinician the same day — or go to urgent care — for:
- Severe, persistent upper-abdominal pain, possibly boring through to your back, with or without vomiting. That is pancreatitis until proven otherwise. (A history of pancreatitis is also a reason for caution before starting at all — it’s on both labels.)
- Right-upper-quadrant pain with fever or yellowing of skin or eyes. Gallbladder — see above.
- Unable to keep fluids down for 24+ hours. Protracted vomiting plus a drug that mutes thirst cues is how dehydration quietly becomes a kidney problem.
- A neck lump, new hoarseness, or trouble swallowing. Almost always something benign — but these are exactly the symptoms the thyroid warning asks you to report.
- Swelling of the face or throat, trouble breathing. That’s not a message to your clinician. That’s 911.
One scheduled-care note that surprises people: anesthesia societies now advise flagging GLP-1 use to your surgical or endoscopy team before any sedation, because after a standard overnight fast your stomach may not be empty.
Zappy clinicians review every case within 24 hours, and dose messages don’t wait for a scheduled visit. The list above is what “don’t wait for the check-in” means.
The boxed warning, plainly
Both molecules caused thyroid C-cell tumors in rodents. Whether that risk translates to humans is unknown — it has not been shown in people, and it has not been ruled out. The practical consequence is a hard line: do not take these drugs with a personal or family history of medullary thyroid carcinoma or MEN 2. Separately, and equally hard: not for use in pregnancy. If you’re pregnant or planning to be, that changes the plan — tell your clinician.
How long is the safety record, really?
Longer than skeptics assume, shorter than forever. The weight-loss trials ran 68–72 weeks. The long tail comes from SELECT (Lincoff et al., NEJM 2023): 17,604 adults with established cardiovascular disease, followed for a mean of more than three years on semaglutide 2.4 mg — the largest long-term dataset in the class. Its headline result ran in the drug’s favor: major adverse cardiovascular events down 20% in relative terms (HR 0.80). Three-plus years of watching 17,604 people is a real safety record. It is not a ten-year record.
Starting with your history in hand
The map above is generic; your risk isn’t. Thyroid history, pancreatitis, pregnancy plans, what your gut already does on a normal week — those are the questions the two-minute intake asks, because they are what moves this map from “the class” to “you.”
What we still don’t know
Two open questions outrank the rest. Duration: SELECT takes the safety record to roughly three years, and these are designed as long-term medications — decade-scale data doesn’t exist because the decade hasn’t happened yet. Composition: DXA substudies tell us lean mass is part of what’s lost, but no trial has tested whether that changes strength, fracture risk, or independence at 70 — or whether two sessions of resistance training a week fully closes the gap. That second readout is the one to watch.
